Researchers conducted a retrospective chart review on patients from an endocrinology clinic who initiated a GLP-1 agonist and/or SGLT-2 inhibitor after receiving U-500 insulin for at least 3 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback